
AcelRx Pharmaceuticals ACRX
Quarterly report 2026-Q1
added 05-13-2026
AcelRx Pharmaceuticals EV - Enterprise Value 2011-2026 | ACRX
Annual EV - Enterprise Value AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.79 M | 23.6 M | 12.8 M | 15.1 M | 109 M | 282 M | 254 M | 172 M | 151 M | 143 M | 147 M | 271 M | 414 M | 96 M | 62.2 M | 13.7 M | -7.15 M | -6.07 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 414 M | -7.15 M | 120 M |
EV - Enterprise Value of other stocks in the Drug manufacturers industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-3.12 M | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
126 M | $ 5.66 | 1.07 % | $ 84.1 M | ||
|
HEXO Corp.
HEXO
|
560 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-974 M | - | -0.1 % | $ 2.03 B | ||
|
DURECT Corporation
DRRX
|
-11 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
-1.35 M | $ 2.67 | -0.37 % | $ 1.02 B | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
2.21 B | $ 39.05 | 3.75 % | $ 1.44 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.01 | 1.5 % | $ 109 M | ||
|
Organogenesis Holdings
ORGO
|
408 M | $ 2.37 | 1.28 % | $ 300 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 22.96 | -0.15 % | $ 1.06 B | ||
|
Aurora Cannabis
ACB
|
330 M | $ 3.14 | 3.13 % | $ 172 M | ||
|
Solid Biosciences
SLDB
|
616 M | $ 7.34 | 2.8 % | $ 642 M | ||
|
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 1.12 | 2.84 % | $ 1.39 M | ||
|
Lannett Company
LCI
|
671 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
146 M | $ 1.06 | -0.47 % | $ 101 M | ||
|
Tilray
TLRY
|
1.96 B | $ 5.06 | 1.61 % | $ 3.13 B | ||
|
Evolus
EOLS
|
467 M | $ 6.67 | -0.89 % | $ 430 M | ||
|
Sundial Growers
SNDL
|
-17.5 M | $ 1.44 | 1.63 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
1.04 B | $ 8.3 | -0.24 % | $ 444 M | ||
|
Veru
VERU
|
80.7 M | $ 3.07 | 2.43 % | $ 45 M | ||
|
Neoleukin Therapeutics
NLTX
|
-80.1 M | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
4.51 M | $ 0.71 | 3.49 % | $ 2.86 M | ||
|
Assertio Holdings
ASRT
|
238 M | $ 23.49 | 0.02 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
56.3 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
715 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
26.7 B | $ 5.08 | 0.4 % | $ 1.88 B | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
251 M | $ 6.72 | 1.05 % | $ 265 M | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
84.7 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
26.3 M | $ 4.33 | 2.36 % | $ 216 M | ||
|
PLx Pharma
PLXP
|
75 M | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
21.2 B | $ 16.46 | -0.12 % | $ 19.3 B | ||
|
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
43.3 M | $ 0.65 | 3.92 % | $ 23.4 M | ||
|
Tricida
TCDA
|
555 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
10.7 M | $ 0.75 | 1.01 % | $ 3.22 M | ||
|
TherapeuticsMD
TXMD
|
26.3 M | $ 2.26 | 2.73 % | $ 26.1 M |